Patent Issued

September 2016.  The USPTO issued a Notice of Allowance for a patent application protecting the company's technology platform.

Patent Issued

September 2016.  The EPO granted a European Patent for the company's application dealing with suppression of cardiovascular side effects in melanocortin analogs intended for therapeutic and related uses.

NIH Grant Awarded

September 2016.  TCI Peptide's was awarded a $2.3 million grant from the National Cancer Institute to further advance research and development of a melanocortin-based therapeutic for cancer cachexia.

Series A Completed

June 2016.  TCI Peptide's completed a $1.7 million financing round through Centennial Investors Angel Investor Network.  Funds will be used to advance the development of applications of the company's technology platform for modifying peptides with applications in human and animal health.

Nationwide Clinical Trial Opened

 

June 2017. TCI Peptide's demonstrated progress toward development path milestones and successfully transitioned to Phase 2 of the National Cancer Institute Grant.

Transition to Phase 2 of NIH Grant

 

May 2017. Clinical trial sites from major veterinary hospital groups were opened to augment recruitment efforts at the University of Missouri School of Veterinary Medicine.